Nang Kuang Pharmaceutical Co., Ltd. (1752) AI Stock Analysis

Nang Kuang Pharmaceutical Co., Ltd.

(TWSE:1752)

Select Model

Rating:65.4Neutral

Price Target:TWD 32.00▲(7.02% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by the company’s conservative balance sheet, solid profitability, and attractive valuation. These strengths are offset by declining revenue, weaker cash conversion, and bearish technical momentum despite oversold indicators.

Positive Factors

Consistent ProfitabilitySustained gross and net profitability indicates that the company continues to convert pharmaceutical sales into meaningful earnings. Although below its 2022 peak, this ongoing profitability provides internal funding capacity and supports resilience through the next several quarters.

Negative Factors

Slowing RevenueFlat-to-declining revenue signals limited near-term expansion in the company’s pharmaceutical business. Without renewed top-line growth, operating leverage and earnings progression may remain constrained, making it harder to rebuild the stronger performance achieved earlier.

Nang Kuang Pharmaceutical Co., Ltd. (1752) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.00B
Dividend Yield: 5.35%
Average Volume (3M): 68.07K
Price to Earnings (P/E): 16.1
Beta (1Y): 0.29
Revenue Growth: -6.10%
EPS Growth: -26.89%
Country: TW
Employees: 552
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Nang Kuang Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Primarily based in Taiwan, Nang Kuang Pharmaceutical Co., Ltd. functions as a pharmaceutical enterprise. Its comprehensive product range includes various sterile injectable forms such as parenterals, aseptic parenterals, lyophilized injections, pre-f...

Nang Kuang Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Financially sound overall, supported by a strong balance sheet and solid profitability. Revenue declined, margins remain below prior highs, and free-cash-flow conversion is relatively weak.

Income Statement

68Positive

Balance Sheet

82Very Positive

Cash Flow

64Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.11B	2.16B	2.20B	2.15B	1.94B	1.78B
Gross Profit	734.20M	768.86M	747.79M	755.56M	694.90M	594.47M
EBITDA	449.85M	478.81M	491.69M	402.70M	591.75M	418.04M
Net Income	203.75M	243.95M	243.41M	198.41M	352.00M	196.11M
Balance Sheet
Total Assets	3.94B	3.82B	3.81B	3.86B	3.58B	3.43B
Cash, Cash Equivalents and Short-Term Investments	383.56M	345.67M	303.37M	378.48M	402.51M	418.41M
Total Debt	684.64M	655.95M	638.45M	605.96M	409.50M	533.54M
Total Liabilities	1.53B	1.33B	1.39B	1.48B	1.17B	1.19B
Stockholders Equity	2.41B	2.48B	2.42B	2.38B	2.41B	2.24B
Cash Flow
Free Cash Flow	142.30M	183.03M	-59.49M	41.87M	275.02M	396.89M
Operating Cash Flow	350.38M	464.08M	466.43M	342.61M	369.19M	556.63M
Investing Cash Flow	-213.42M	-281.94M	-372.39M	-329.51M	-109.85M	-291.48M
Financing Cash Flow	-82.89M	-138.02M	-170.97M	-35.77M	-275.31M	-114.48M

Nang Kuang Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1752 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1752	65Neutral	TWD 3.02B	16.07	―	5.35%	-6.10%	-26.89%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:3226	42Neutral	TWD 3.17B	350.04	―	1.02%	-32.93%	-88.49%
TW:6461	42Neutral	TWD 2.94B	-5.89	―	―	-57.87%	-21.67%
TW:4113	37Underperform	TWD 2.96B	-14.33	―	6.64%	-90.66%	-196.01%
TW:6875	37Underperform	TWD 3.24B	-9.12	―	―	-69.26%	-24.53%

* General Sector Average

Performance Comparison

TW:1752 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1752	Nang Kuang Pharmaceutical Co., Ltd.	29.90	-6.84	-18.62%
TW:3226	LFA Co Ltd	49.25	0.15	0.31%
TW:4113	We&Win Diversification Co., Ltd.	12.80	-8.90	-41.01%
TW:6461	Intech Biopharm Ltd	26.55	1.66	6.65%
TW:6838	Formosa Pharmaceuticals, Inc.	20.60	-6.85	-24.95%
TW:6875	Pharmosa Biopharm Inc.	25.05	-24.60	-49.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Nang Kuang Pharmaceutical Co., Ltd. AI Stock Analysis